Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer von Tsimberidou, Apostolia-Maria, Shaw, Jamie V, Juric, Dejan, Verschraegen, Claire, Weise, Amy M, Sarantopoulos, John, Lopes, Gilberto, Nemunaitis, John, Mita, Monica, Park, Haeseong, Ellers-Lenz, Barbara, Tian, Hui, Xiong, Wenyuan, Kaleta, Remigiusz, Kurzrock, Razelle

Volltext

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas von Gounder, Mrinal M, Bauer, Todd M, Schwartz, Gary K, Weise, Amy M, LoRusso, Patricia, Kumar, Prasanna, Tao, Ben, Hong, Ying, Patel, Parul, Lu, Yasong, Lesegretain, Arnaud, Tirunagaru, Vijaya G, Xu, Feng, Doebele, Robert C, Hong, David S

Volltext

First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors von Garrido‐Laguna, Ignacio, Krop, Ian, Burris, Howard A., Hamilton, Erika, Braiteh, Fadi, Weise, Amy M., Abu‐Khalaf, Maysa, Werner, Theresa L., Pirie‐Shepherd, Steven, Zopf, Christopher J., Lakshminarayanan, Mani, Holland, Jaymes S., Baffa, Raffaele, Hong, David S.

Volltext

Possible case of levofloxacin-induced thrombocytopenia von Salloum, Ralph, Liu, Chin Y, Weise, Amy M

Volltext

Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression von Radkevich-Brown, Olga, Piechocki, Marie P, Back, Jessica B, Weise, Amy M, Pilon-Thomas, Shari, Wei, Wei-Zen

Volltext

New Options for the Adjuvant Treatment of Cutaneous Melanoma? von Weise, Amy M., Flaherty, Lawrence E.

Volltext

Fatal Liver Failure in a Patient on Acetaminophen Treated with Sunitinib Malate and Levothyroxine von Weise, Amy M, Liu, Chin Y, Shields, Anthony F

Volltext

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer von Weise, Amy M, Gadgeel, Shirish

Volltext

Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression von Fu, Jiaqi, Weise, Amy M, Falany, Josie L, Falany, Charles N, Thibodeau, Bryan J, Miller, Fred R, Kocarek, Thomas A, Runge-Morris, Melissa

Volltext

False positive PET scan in patients with treated malignancy following COVID-19 vaccination von Slota, Alexander Antoni, Parmar, Vrajesh, Weise, Amy M., Wang, Ding

Volltext

Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity von Whittington, Paula J, Radkevich-Brown, Olga, Jacob, Jennifer B, Jones, Richard F, Weise, Amy M, Wei, Wei-Zen

Volltext

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer von Fong, Lawrence, Hotson, Andrew, Powderly, John D, Sznol, Mario, Heist, Rebecca S, Choueiri, Toni K, George, Saby, Hughes, Brett G M, Hellmann, Matthew D, Shepard, Dale R, Rini, Brian I, Kummar, Shivaani, Weise, Amy M, Riese, Matthew J, Markman, Ben, Emens, Leisha A, Mahadevan, Daruka, Luke, Jason J, Laport, Ginna, Brody, Joshua D, Hernandez-Aya, Leonel, Bonomi, Philip, Goldman, Jonathan W, Berim, Lyudmyla, Renouf, Daniel J, Goodwin, Rachel A, Munneke, Brian, Ho, Po Y, Hsieh, Jessica, McCaffery, Ian, Kwei, Long, Willingham, Stephen B, Miller, Richard A

Volltext

A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600 -mutated solid tumors von Piha-Paul, Sarina A., Nagpal, Seema, Weise, Amy M., Braiteh, Fadi S., Chen, Chen, Huang, Charles Qing, Liu, William, Hu, Yong, Yang, Zane, Tsai, Katy K.

Volltext

Profiling of targetable aberrations in advanced sarcoma von Hamid, Muhammad Saad, Al Masalmeh, Nada, Poorman, Kelsey Anne, Weise, Amy M.

Volltext

XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers von Hamilton, Erika P., Chaudhry, Arvind, Spira, Alexander I., Adams, Sylvia, Abuhadra, Nour, Giordano, Antonio, Parajuli, Ritesh, Han, Hyo S., Weise, Amy M., Marchesani, Aubri, Gupta, Divya, Josephs, Kate, Kalinsky, Kevin

Volltext

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis von Hamid, Omid, Lewis, Karl D., Weise, Amy M., McKean, Meredith, Papadopoulos, Kyriakos P., Crown, John, Thomas, Sajeve Samuel, Girda, Eugenia, Kaczmar, John M., Kim, Kevin B., Lakhani, Nehal, Yushak, Melinda Lynne, Mani, Jayakumar, Fang, Fang, Brennan, Laura, Jankovic, Vladimir, Paccaly, Anne Josee, Masinde, Sheila, Lowy, Israel, Gullo, Giuseppe

Volltext

A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis von Mehmi, Inderjit, Lewis, Karl D., Weise, Amy M., McKean, Meredith, Papadopoulos, Kyriakos P., Crown, John, Thomas, Sajeve Samuel, Girda, Eugenia, Kaczmar, John M., Kim, Kevin B., Lakhani, Nehal J., Yushak, Melinda Lynne, Hamid, Omid, Mani, Jayakumar, Fang, Fang, Lowy, Israel, Gullo, Giuseppe

Volltext

Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population von Vaishampayan, Ulka N., Kim, Seongho, Karwa, Jaswinder, Mamdani, Hirva, Lange, Lisa, Harfoot, Danielle, Jamison, Andrea, Williams, Lindsay, Wilson, Kelley, Weise, Amy M.

Volltext

Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities von Tsimberidou, Apostolia Maria, Verschraegen, Claire F., Weise, Amy M., Sarantopoulos, John, Lopes, Gilberto, Nemunaitis, John J., Hicking, Christine, Shaw, Jamie, Kaleta, Remigiusz, Kurzrock, Razelle

Volltext

CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC) von Boni, Valentina, Burris III, Howard A., Liu, Joyce F., Spira, Alexander I., Arkenau, Hendrik-Tobias, Fidler, Mary J., Rosen, Lee S., Sweis, Randy F., Uboha, Nataliya Volodymyrivna, Sanborn, Rachel E., O'Neil, Bert, Harding, James J., LoRusso, Patricia, Weise, Amy M., Garcia-Corbacho, Javier, Victoria, Iván, Frye, John W., Li, Rachel, Stroh, Mark, Meric-Bernstam, Funda

Volltext